

## ICBP Phase 1 Researchers

Research question	Lead researchers
Survival Benchmark 1995-2007 (4 cancer types)	Michel Coleman, Sarah Walters, Bernard Racht
Public awareness, attitudes and beliefs about cancer	Jane Wardle, Lindsay Forbes, Alice Simon
Role of primary care doctors and health systems in diagnosis	Peter Rose, Greg Rubin, Sarah Brown
Measuring time intervals and pathways from diagnosis to treatment	Peter Vedsted, David Weller, Usha Menon
Exploring the impact of registry practices and comorbidity on short term outcomes	Michael Eden, Eva Morris, Margreet Lüchtenborg

## ICBP Phase 1 Working groups

### Survival benchmark 1995-2007

**Research leaders:** Jan Adolfsson (Karolinska University Hospital, Stockholm, Sweden); Heather Bryant (Canadian Partnership Against Cancer, Toronto, Canada); Michael Coory (Cancer Council Victoria, Melbourne, Australia); David Forman (International Agency for Research on Cancer, Lyon, France); Marianne L Gjerstorff (Danish Cancer Registry, Copenhagen, Denmark); Tom Borge Johannesen (Norwegian Cancer Registry, Oslo, Norway); Mats Lambe (Karolinska Institutet, Stockholm, Sweden); David Meechan (Trent Cancer Registry, Sheffield, UK); Richard Middleton (Northern Ireland Cancer Registry, Belfast, UK); Janey Shin (Canadian Partnership Against Cancer, Toronto, Canada); John Steward (Welsh Cancer Intelligence and Surveillance Unit, Cardiff, UK); Elizabeth Tracey (Cancer Institute NSW, Sydney, Australia).

**Cancer registries:** Juanita Hatcher, Carol Russell (Alberta Health Services, Edmonton, Canada); Andy Coldman, Mark Elwood, David Levy, Colleen E McGahan (British Columbia Cancer Agency, Vancouver, Canada); Dhali Dhaliwal, Donna Turner (CancerCare Manitoba, Winnipeg, Canada); Loraine Marrett, John McLaughlin, Kamini Milnes, Diane Nishri, Michael Sherar (Cancer Care Ontario, Toronto, Canada); Gerda Engholm (Danish Cancer Society, Copenhagen, Denmark); Eva J Morris, James Thomas (Northern and Yorkshire Cancer Registration and Information Service, Leeds, UK); Karen Linklater (Thames Cancer Registry, London, UK); Rebecca Elleray, David Meechan, Andy Smith (Trent Cancer Registry, Sheffield, UK); Gill Lawrence (West Midlands Cancer Intelligence Unit, Birmingham, UK); Finian Bannon, Colin Fox (Northern Ireland Cancer Registry, Belfast, UK); Ceri White (Welsh Cancer Intelligence and Surveillance Unit, Cardiff, UK).

**Clinical committee:** Jonas Bergh (Karolinska Institutet, Stockholm, Sweden); John Boyages (Westmead Breast Cancer Institute, Sydney, Australia); Michel Boyer (Sydney Cancer Centre, Sydney, Australia); John Butler (Department of Health, London, UK); Peter Clark (Clatterbridge Centre for Oncology, Liverpool, UK); Bill Evans (Juravinski Cancer Centre at Hamilton Health Sciences, Cancer Care Ontario, Toronto, Canada); Hilary Fielder (Velindre NHS Trust, Cardiff, UK); Tony Fields (Alberta Health Services, Edmonton, Canada); Paul Finan (Leeds Teaching Hospitals NHS Trust, Leeds, UK); Tommy Fornander, Södersjukhuset, Stockholm, Sweden); Neville Hacker (Royal Hospital for Women, Sydney, Australia); Louise Hanna (Velindre NHS Trust, Cardiff, UK); Thomas Hogberg (Skåne University Hospital, Lund, Sweden); Charlotte Hosbond (National Board of Health, Copenhagen, Denmark); Karl Kölbeck (Karolinska University Hospital, Stockholm, Sweden); Martin Lee (University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK); Peter Barrett Lee (Velindre NHS Trust, Cardiff, UK); Jason Lester (Velindre NHS Trust, Cardiff, UK); Mark Levine (McMaster University, Hamilton, Canada); Gudrun Lindmark (Skåne University Hospital, Malmö-Lund, Sweden); Tim Maughan (Velindre NHS Trust, Cardiff, UK); Usha Menon (University College London, London, UK); Ian Moneypenny (Cardiff & Vale NHS Trust, Cardiff, Wales, UK); Andy Nordin (East Kent University Hospitals, Canterbury, UK); Julietta Patnick (NHS Cancer Screening, Sheffield, UK); Mick Peake (Department of Respiratory Medicine, Leicester, UK); Andrew Radcliffe (Llandough Hospital, Penarth, UK); Barry Rosen (University of Toronto, Toronto, Canada); Annika Sjövall (Karolinska University Hospital, Stockholm, Sweden); Allan Spigelman (University of New South Wales, Sydney, Australia); Gunnar Wagenius (Uppsala University Hospital, Uppsala, Sweden); Fredrik Wärnberg (Uppsala University Hospital, Uppsala, Sweden); Michael Williams (Addenbrooke's, Cambridge, UK); Ian Williamson (Royal Gwent Hospital, Newport, UK).

**Central Analytic Team** (Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK): Claudia Allemani (also Analytical Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Michel P Coleman, Libby Ellis, Camille Maringe, Ula Nur, Manuela Quaresma, Bernard Rachet, Sarah Walters.

**Epidemiology Reference Group:** Bruce Armstrong (University of Sydney, Sydney, Australia); Paul Dickman (Karolinska Institutet, Stockholm, Sweden); Paul Lambert (University of Leicester, Leicester, UK); Dianne O’Connell (Cancer Council New South Wales, Sydney, Australia); Milena Sant (Istituto Nazionale dei Tumori, Milan, Italy); Hannah Weir (Centers for Disease Control and Prevention, Atlanta, USA).

## Public awareness, attitudes and beliefs about cancer

Michael Donnelly (Queen’s University Belfast, Belfast, UK); David Donnelly (Queen’s University Belfast, Belfast, UK); Anette Fischer Pedersen (Aarhus University, Aarhus, Denmark); Deb Keen (Canadian Partnership Against Cancer, Toronto, Canada); Chris Roberts (Welsh Cancer National Specialist Advisory Group, Cardiff, UK); James Kite (Cancer Institute New South Wales, New South Wales, Australia); Blythe O’Hara (Cancer Institute New South Wales, New South Wales, Australia); Donna Perez (Cancer Institute New South Wales, New South Wales, Australia); Lisa Petermann (Canadian Partnership Against Cancer, Toronto, Canada); Chris Roberts (Welsh Cancer National Specialist Advisory Group, Cardiff, UK); Melanie Wakefield (Cancer Council Victoria, Victoria, Australia); Christian Wulff (Aarhus University, Aarhus, Denmark).

## Role of primary care doctors and health systems in diagnosis

Andriana Barisic (Cancer Care Ontario, Toronto, Ontario, Canada); Martin Dawes (University of British Columbia, Vancouver, Canada); Diana Dawes (University of British Columbia, Vancouver, Canada); Mark Elwood (University of Auckland, Auckland, New Zealand); Kirsty Forsdike (Department of General Practice, Victoria, Australia); Eva Grunfeld (University of Toronto, Ontario, Canada); Nigel Hart (Queen’s University Belfast, Belfast, UK); Breann Hawryluk (Cancer Care Manitoba, Winnipeg, Canada); Gerald Konrad (University of Manitoba, Winnipeg, Canada); Anne Kari Knudsen (Norwegian University of Science and Technology, Trondheim, Norway); Magdalena Lagerlund (Karolinska Institute, Stockholm, Sweden); Claire McAulay (University of Sydney, Sydney, Australia); Jin Mou (University of British Columbia, Vancouver, Canada). Richard D Neal (Bangor University, Wrexham, UK); Marie Pirotta (Department of General Practice, Carlton, Australia); Jeffrey Sisler (University of Manitoba, Winnipeg, Canada); Berit Skjødberg Toftegaard (Aarhus University, Aarhus, Denmark); Hans Thulesius (Lund University, Lund, Sweden); Peter Vedsted (Aarhus University, Aarhus, Denmark); David Weller (University of Edinburgh, Edinburgh, UK); Jane Young (The University of Sydney, Australia).

**Academic Reference Group:** Jon Emery (University of Melbourne and University of Western Australia, Australia); Niek de Wit (University Medical Centre, Utrecht, The Netherlands); Roger Jones (King’s College, London, UK); Jean Muris (Maastricht University, The Netherlands); Frede Olesen (University of Aarhus, Denmark).

## Measuring time intervals and pathways from diagnosis to treatment

Sigrun Saur Almberg (Norwegian University of Science and Technology, Trondheim, Norway); Chantelle Anandan (University of Edinburgh, Edinburgh, UK); Andriana Barisic (Cancer Care Ontario, Toronto, Canada); Jackie Boylan (Queen’s University Belfast, Belfast, UK); Conan Donnelly (Queen’s University Belfast, Belfast, UK); Evangelia Ourania Fourkala (University College London, London, UK); Alina Zalounina Falborg (Aarhus University, Aarhus, Denmark); Anna Gavin (Queen’s University Belfast, Belfast, UK); Eva Grunfeld (University of Toronto, Ontario, Canada); Victoria Hammersley (University of Edinburgh, Edinburgh, UK); Breann Hawryluk (Cancer Care Manitoba, Winnipeg, Canada); Therese Kearney (Queen’s University Belfast, Belfast, UK); Jacqueline Kelly (Queen’s University Belfast, Belfast, UK); Anne Kari Knudsen (Norwegian University of Science and Technology, Trondheim, Norway); Mats Lambe (Karolinska Institutet, Stockholm, Sweden); Rebecca Law (Bangor University, Wrexham, UK); Yulan Lin (Norwegian University of Science and Technology, Trondheim, Norway); Martin Malmberg (Lund University Hospital, Lund, Sweden); Usha Menon (University College London, London, UK); Kerry Moore (Queen’s University Belfast, Belfast, UK); Richard D Neal (Bangor University, Wrexham, UK); Donna Turner (Cancer Care Manitoba, Winnipeg, Canada); Peter Vedsted (Aarhus University, Aarhus, Denmark); David Weller (University of Edinburgh, Edinburgh, UK); Vicki White (Cancer Council Victoria, Melbourne, Australia); Henry Jensen (Aarhus University, Aarhus, Denmark).

**Academic Reference Group:** Jan Willem Coebergh (Erasmus Universiteit Rotterdam, Rotterdam, the Netherlands); Jon Emery (University of Melbourne and University of Western Australia, Australia); Stefan Bergström (Department of Oncology, Gävle, Sweden); Monique E van Leerdam (Erasmus MC University Medical Centre, the Netherlands); Marie-Louise Essink-Bot (Academic Medical Centre, Amsterdam University, the Netherlands); Una MacLeod (Hull-York Medical School, UK).

## Exploring the impact of registry practices and comorbidity on short term outcomes

Mike Eden (Public Health England, London, UK); Michelle Griffin (Public Health England, London, UK); Jem Rashbass (Public Health England, London, UK); Eva Morris (Leeds Institute of Cancer and Pathology, Leeds, UK); Mick Peake (Public Health England, London, UK); Margreet Luchtenborg (King's College London, London, UK); Victoria Coupland (Public Health England, London, UK); Daniela Tateru (Public Health England, London, UK); Deirdre Fitzpatrick (Queen's University Belfast, Belfast, UK); Conan Donnelly (Queen's University Belfast, Belfast, UK); Dyfed W Huws (Public Health Wales, Cardiff, UK); Janet Warlow (Welsh Cancer Intelligence & Surveillance Unit, Cardiff, Wales); Ceri White (Welsh Cancer Intelligence & Surveillance Unit, Cardiff, Wales); David H Brewster (Scottish Cancer Registry, Edinburgh, UK); Andy Deas (Scottish Cancer Registry, Edinburgh, UK); Anne-Kari Knudsen (Norwegian University of Science and Technology, Trondheim, Norway); Yulan Lin (Norwegian University of Science and Technology, Trondheim, Norway); Bjørn Møller (Cancer Registry of Norway, Oslo, Norway); Donna Turner (Cancer Care Manitoba, Winnipeg, Canada); Craig Earle (Cancer Care Ontario, Toronto, Canada); Mary-Jane King (Cancer Care Ontario, Toronto, Canada); Diane Nishri (Cancer Care Ontario, Toronto, Canada); Lorraine Shack (Alberta Health Services, Calgary, Canada); Roger Milne (Cancer Council Victoria, Melbourne, Australia); Luc te Marvelde (Cancer Council Victoria, Melbourne, Australia); Deborah Baker (Cancer Institute NSW, Sydney, Australia); Richard Walton (Cancer Institute NSW, Sydney, Australia).

**Academic Reference Group:** Henrik Moller (Kings College London, UK); Paul Lambert (University of Leicester, UK); Paul Dickman (Karolinska Institute, Sweden); Hannah Weir (Centre for Disease Control and Prevention, Atlanta, USA).